Dosing initiated for Innovent Bio's IBI322 in China
Innovent Biologics announced it has dosed the first patient for its early-stage trial in China for IBI322, a recombinant anti-CD47/PD-L1 bispecific antibody designed to treat advanced malignancies in patients who failed standard therapy. The trial will assess the drug's initial anti-tumor efficacy, safety and tolerability. Seeking Alpha (free registration) (8/3)
Read full article now.
Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!